Associate Scientist position open
Take your Next Step with us!
ISO Accreditation for the Diagnostic Assay Services Lab
On February 18, 2019 PamGene has received the Certificate of Approval by Lloyd's Register for the ISO 13485:2016 for it's Management System.
New Career Opportunities at PamGene
PamGene's NHR platform in major EDCMET Consortium
Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways (EDCMET)
At ASCO 2018: Predictive biomarkers for immunotherapy in Melanoma
PamGene is active in the area of diagnostics research and is in the process of developing clinical biomarkers for therapy response. There is an urgent need to properly predict clinical response to checkpoint inhibitor therapy. In a multi-center effort, we presented a landmark poster at this year's American Society of Clinical Oncology (ASCO) annual Meeting, held in Chicago, from June 1-5, 2018. We showed that the PamChip blood test can serve as a rapid predictive liquid biomarker test to stratify patients prior to immunotherapy, by measuring kinase activity in patients' blood prior to therapy start. We are proud and excited to announce that the validation study is currently underway. Please contact us to discuss these new data and the implications for the field.
AACR 2018 follow-up
April 2018 This year's American Association for Cancer Research (AACR) Annual Meeting, held from April 14th to 18th in Chicago, had a focus on "Driving Innovative Cancer Science to Patient Care", a theme closely fitting PamGene's way forward.
Society of Toxicology Meeting: Nuclear Receptor Applications
Through our key collaborations with U.S. NIEHS, and Penn State University, notable applications of PamGene's Nuclear receptor assay in advancing the Toxicology field were presented at the 2018 Society of Toxicology Meeting (Mar 11-15, San Antonio).
2017 in review
Review our 2017 publications that have described applications of the PamGene technology in fundamental, biomarker, clinical and discovery research.
Spotlight on Uveal Melanoma: The UM CURE PROJECT
Uveal melanoma is a cancer (melanoma) of the eye occurring in the uvea (iris, ciliary body, and choroid) and arising from uveal melanocytes (pigment cells). The "UMCure2020" Uveal Melanoma (UM) project aims to develop an effective therapy for the treatment of the metastases of this type of eye cancer. An essential step to achieve this is to increase knowledge about the tumor biology of this rare eye cancer.
New Protein Tyrosine Kinase PamChip released
October 16th, 2017: PamGene has released a new redesigned Protein Tyrosine Kinase PamChip, the PTK-196, with additional peptides and increased coverage.
PamGene Posters at the Japanese Cancer Association Meeting
Dr. Tadashi Kondo and researchers from the National Cancer Center (NCC) presented posters with novel insights into therapeutic target discovery and strategy using PamGene data, at the 76th Annual meeting of the Japanese Cancer Association, September 28th-30th 2017.
Prognostic biomarkers for lung cancer
Dr. Stephan Arni and researchers at the University of Zurich, Switzerland have shown how kinomic profiling can be used to discover prognostic biomarkers in lung cancer, that could potentially provide therapy guiding information prior to lung cancer patient therapy.
AACR 2017: The Path forward
Immune Checkpoints and Immunosurveillance, Molecular Targeted Therapies, Biomarker Discovery, Drug Resistance and Growth Signalling Pathways: PamGene and our collaborators presented key advancements in these areas with 5 posters at the Annual Meeting of the American Association of Cancer Research in Washington DC (April 1st to 5th, 2017).
At SOT 2017: New Applications of NHR assays in TOX
Through our key collaborations with U.S. EPA, NIH and Bayer, notable applications of PamGene's Nuclear receptor assay in advancing the Toxicology field were presented, in a lecture and poster at this year's Society of Toxicology Meeting.
PamChips for interrogating the human kinome
A recent review in Biochemical Society Transactions has described PamGene's kinome profiling technology as one of the "advanced" and a "primary" technology currently used for kinome analysis...
2016 in Review
PamGene links to new applications in 2016
Download the AACR 2016 Poster on the Clinical efficacy of Sunitinib
Clinical efficacy of Sunitinib from blood samples of mRCC patients? Novel and interesting findings were presented at the 2016 annual meeting of the American Association of Cancer Research (AACR) by Galle No from the group of Prof. Vidal, Cochin Hospital, Paris. These researchers sought to find out whether PBMCs could be an interesting model to obtain biomarkers predicting the clinical efficacy of Sunitinib, in mRCC.
Metabolic disorders on the horizon with PamGene technology
Researchers from Professor Fajas' group at the University of Lausanne, Switzerland, and their collaborators, have revealed novel and exciting insights about how CDK4 participates in adipose tissue biology and in insulin signalling.
PamGene exhibited at the Innovation for Health Conference
Yes! We were there at the Innovation for Health Conference on February 18th 2016 at the World Trade Center (WTC), Rotterdam, The Netherlands. We showcased more about our new efforts in the diagnostics arena.
Kinase activity decreases with Alzheimer's disease progression
Researchers from the Neuroscience Campus, VU University Medical Center, Amsterdam, The Netherlands have discovered that protein kinase activity decreases with progression of Alzheimers Disease (AD) Pathology and is evident early on, at pre-clinical stages.
Insights into nuclear receptor functions in 4 publications this year
Interesting publications in 2015, from research groups that have used PamGene's Nuclear receptor profiling technology, highlight novel applications that provide insights into nuclear receptor function.
Innovative Toxicology Collaboration receives major funding
ZonMw in collaboration with the German Federal Ministry of Education and Research (BMBF) approved four projects for Eur 750,000, under Innovative Systems Toxicology for Alternatives to Animal Testing (InnoSysTox). The focus is on the development of innovative systems biology 3Rs methods in the field of toxicology and / or the application of new and existing systems biology 3Rs methods in the field of toxicology.
A step closer to realizing personalized lung cancer treatment
A DutchGerman public-private consortium of PamGene, GenXpro and the University Medical Center Groningen has been awarded a research grant from the EU Eurostars-2 program for the Triple T project of 1.55 million: Rationalized Tailored Targeted Therapy for Cancer.
Which kinases phosphorylate peptides on the PamChip?
Kinase activity profiling with PamChip peptide microarrays can be used to study signal transduction in lysates of cell lines and clinical samples. Peptides on the PamChip arrays represent phospho-sites in the human proteome. Phosphorylation of peptides by tyrosine (PTK) or serine-threonine (STK) kinases that are active in a sample is detected in the kinase activity profiling assay.
At AACR: Kinase activity profiling in thyroid and renal cancers: View our Posters
PamGene and it's collaborators presented exciting posters at the Annual Meeting of the American Association of Cancer Research in Philadelphia, Pennsylvania (April 18th to 22nd, 2015).
Download SOT 2015 posters highlighting the Nuclear Receptor platform Applications.
Ren Houtman from PamGene, with collaborators from NCATS, NIH, Bethesda, MD, USA and Division of Toxicology, Wageningen University, Wageningen, Netherlands presented two very interesting posters at the Society of Toxicology's annual meeting, highlighting the potential of the unique Nuclear Receptor MARCoNI platform in Toxicology research.
Spotlight on Toxicology applications of the PamGene platform
With the Society of Toxicology's annual meeting fast approaching, PamGene released a Newsletter with a focus on Toxicology.
UABs Kinome Core scores a hatrick with 3 new publications
UABs Kinome Core scores a hatrick with 3 new publications involving PamGenes kinase activity profiling platform!
ACEA and PamGene join forces to accelerate kinase research
Scratch Beneath the Surface! Combine xCELLigence RTCA phenotypic assays with PamGene's Flow-Through Kinase Array. See signalling pathways responsible for your Cell Index curves.
10-year kinase inhibitor research in a nutshell
Our white paper (free download) describes trends over a decade of small molecule Protein Kinase Inhibitor (PKI) research by mining thousands of American Society for Cancer Research (AACR) abstracts covering the period of 2004-2013. You can access relevant information relating to drug discovery and research that could be important for you!
MARCoNI assay shows resveratrol binds ER-alpha
Researchers at The Scripps Research Institute recently published key findings in eLIFE, that revealed "molecular secrets" behind Resveratrol's health benefits. They found that resveratrol controls the bodys inflammatory response as a binding partner with the estrogen receptor without stimulating estrogenic cell proliferation. PamGene's MARCoNI assay contributed in revealing key insights in this process.
At the AACR, interesting applications of PamGene's Kinase activity profiling technology were highlighted
PamGene invites you to view four landmark posters that were presented with our collaborators at the American Association for Cancer Research (AACR) Annual Meeting 2014.
3 Posters presented at the SOT give further insight into PamGene's Nuclear Receptor Applications
PamGene is pleased to announce that 3 Posters were presented at the 2014 Society of Toxicology (SOT) Annual meeting, together with our collaborators. These studies highlight novel applications of our Nuclear Receptor Platform.
Kinase activity profiling tool to reveal molecular mechanisms in latent HIV-1
In order to better understand the molecular biology of HIV-1 latency, Alexandra Duverger et al from the Department of Medicine of the University of Alabama in the USA, carried out a study in which the PamGene platform was used. This study was published in January in the Journal of Virology.
Publication on a detailed analysis of a new kinase inhibitor for acute myeloid leukemia
In January 2014, an article was published about a study into AKN-028, an novel tyrosine kinase inhibitor that targets acute myeloid leukemia (AML). For this study, the PamChip platform was used. AKN-028 is presently undergoing investigation in a Phase I/II study.
Promising proof of concept for small molecule modality to treat non-small cell lung cancer
Ichiro Kadawa et al., from the Department of Medicine of the University of Chicago, have published an article on a study into a new small molecule modality to treat non-small cell lung cancer (NSCLC). The findings, acquired with the Pamstation12, offer a robust preclinical proof of concept for dual targeting of the MET and RON kinases.
Cancer research in zebrafish with the PamGene platform
A new study on cancer research in zebrafish was published in September 2013. Rian Hanan et al looked into the ERK2 pathway and concluded that constitutive activation of this pathway leads to enhanced proliferation. Zebrafish models are commonly used to study developmental biology. As pathology and molecular mechanisms of tumor formation between humans and zebrafish are similar, zebrafish cancer models are very valuable for a better understanding of pathogenesis.
Poster presentation during Nuclear Receptor Research Network
On Thursday 21st of November, the annual meeting of the Nuclear Receptor research Network (NRRN) took place in Utrecht. PamGene was one of the sponsors of this event. Our dedicated nuclear receptor expert Ren Houtman presented a poster on resistance to endocrine therapy.
PamStation12 demonstrated at MipTech 2013 in Basel
Our Swiss distributor, Bucher, is golden sponsor of MipTech 2013, the leading European Event for Drug Discovery. They have a big booth at the congress where they exhibit all kinds of technology that can be relevant to drug development processes. Of course, the PamGene technology cannot be left out.
Article in LabVision about PamGene platform
In the September edition of LabVision, an elaborate article on PamGene's technology has been published. LabVision is a Dutch knowledge platform for laboratories.
PamGene involved in new publication on markers in wild-type metastatic malignant melanoma
In August, PLOSone published a paper of Andliena Tahiri, PhD, from the Department of Clinical Molecular Biology and Laboratory Sciences, Akershus University Hospital, Norway. In her study, she tried to find new markers for targeted therapy for patients with wild-type metastatic malignant melanoma.
Tissue Bank Project with Jeroen Bosch Hospital prolonged
PamGene and Jeroen Bosch Hospital, a large Dutch peripheral hospital, prolonged their collaboration. This collaboration started three years ago and aimed at developing a procedure to collect and store fresh human tumour tissue and starting a biobank with tumour tissue samples of colon and breast cancer patients. Early this year, 250 of these samples have been collected, enabling the performance of clinical studies based on PamGenes kinase activity profiling platform.
New compound able to select the positive effects of cortisol
Dr. Onno Meijer from LUMC in The Netherlands published an article in the scientific journal PNAS on his latest research. Together with PamGene, and researchers from several other institutes, he performed a study into a new compound that is able to imitate positive effects of cortisol and inhibits adverse effects.
Kinase profiling reveals potential target in prostate cancer
This week, a new PamStation study by the group of prof. Anne Hansen Ree at the Department of Oncology, Akershus University Hospital in Norway, was published in PLOS one. In this study, the researchers, Kathrine Re et al., investigated the mechanism that leads to castration resistant prostate cancer.
PamGene technology involved in lecture and poster on ESMO Stockholm
During the 2011 ESMO in Stockholm, two scientist reported on their development in the use of the PamGene technology. Kathrine Re gave a lecture titled Protein Kinase Activity and Therapy Response. Dr Koh presented a poster on his study of the identification of biomarkers to predict drug response in scirrhous gastric cancer cell lines. For both studies, tyrosine kinase activity profiling with PamChip microarrays was used.
14th World Conference on Lung Cancer
PamGenes poster presentation at the ASCO
PamGenes poster presentation receives positive reactions during discussion session at the American Society of Clinical Oncologists (ASCO) meeting in Chicago. Dr. Riet Hilhorst, senior scientist at PamGene, presented the results of PamGenes participation in a clinical trial for non-small cell lung cancer, organised by Dr. Houke Klomp from the Netherlands Cancer Institute (NKI), at the 2011 ASCO Annual Meeting.